Analyst Ratings for Phathom Pharmaceuticals (PHAT)
PHAT Rating Summary
PHAT Price Target Summary
- Highest: $28.00 (H.C. Wainwright)
- Lowest: $10.00 (Goldman Sachs)
- Average: $19.00
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$19.00 (+108.3%)
* Over Last 12-Mos
Rating Score: 8.9 / 10
Percentile Rank: 89%
Avg. $ Target:
$19.00 (+108.3%)
* Over Last 12-Mos
Rating Score: 8.9 / 10
Percentile Rank: 89%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/9/2023 | H.C. Wainwright | Matthew Caufield | New Coverage | Buy (N/A) |
28.00 (N/A) |
14.72 (9.12) |
-38.04% | Details |
| 5/11/2023 | Evercore ISI | Umer Raffat | Upgrade | Outperform (In Line) |
N/A (N/A) |
12.43 (9.12) |
-26.63% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
